Epitope mapping of SARS-CoV-2 Spike protein using naturally-acquired immune responses to develop monoclonal antibodies


Por: López-Aladid, R, Bueno-Freire, L, Farriol-Duran, R, Porta-Pardo, E, Aguilar, R, Vidal, M, Jiménez, A, Cabrera, R, Vázquez, N, López-Gavín, A, Moncunill, G, Carrascal, M, García, T, Lozano, M, García-Basteiro, AL, Dobaño, C, Pazos, MD, Estevez, MC, Lechuga, LM, Torres, A and Fernández-Barat, L

Publicada: 9 may 2025 Ahead of Print: 9 may 2025
Resumen:
COVID-19 vaccination strategies are already available almost worldwide. However, it is also crucial to develop new therapeutic approaches, especially for vulnerable populations that may not fully respond to vaccination, such as the immunocompromised. In this project, we predicted 25 B-cell epitopes in silico in the SARS-CoV-2 Spike (S) protein and screened these against serum and plasma samples from 509 COVID-19 convalescent patients. The aim was to identify those epitopes with the highest IgG reactivity to produce monoclonal antibodies against them for COVID-19 treatment. We implemented Brewpitopes, a computational pipeline based on B-cell epitope prediction tools, such as BepiPred v2.0 and Discotope v2.0, and a series of antibody-epitope accessibility filters. We mapped the SARS-CoV-2 S protein epitopes most likely to be recognised by human neutralizing antibodies. Linear and structural epitope predictions were included and were further refined considering accessibility factors influencing their binding to antibodies like glycosylation status, localization in the viral membrane and accessibility on the 3D-surface of S. Blood samples were collected from 509 COVID-19 patients prospectively recruited 35 days after symptoms initiation, positive RT-qPCR or hospital/ICU discharge. Presence of IgG against SARS-CoV-2 was confirmed by lateral flow immunoassays. Epitopes immunogenicity was tested through the analysis of IgG levels and seropositivity in the convalescent serum and plasma samples and 126 pre-pandemic negative controls by Luminex to identify those with the highest reactivity. The seropositivity cut-offs for each epitope were calculated using a set of 126 pre-pandemic samples as negative controls (NC). Twenty-five SARS-CoV-2 S epitopes were predicted in silico as potentially the most immunogenic. These were synthesized and tested in a multiplex immunoassay against sera/plasmas from convalescent COVID-19 patients (5.7% asymptomatic, 35.6% mild, 13.8% moderate, 23% severe and 22% unknown because of anonymous donation). Among the 25 epitopes tested, 3 exhibited significantly higher IgG reactivity compared to the rest. The proportion of seropositive patients towards these 3 epitopes, based on median fluorescence intensity (MFI or Log10 MFI) above that from NC, ranged between 11 and 48%. Two out of the three most immunogenic epitopes were scaled up, resulting in the generation of two monoclonal antibodies (mAbs). These two mAbs exhibited comparable levels of S protein affinity to commercialized mAbs. Our data shows that the candidate S epitopes predicted in silico are recognised by IgG present in convalescent serum and plasma. This evidence suggests that our computational and experimental pipeline is able to yield immunogenic epitopes against SARS-CoV-2 S. These epitopes are suitable for the development of novel antibodies for preventive or therapeutic approaches against COVID-19.

Filiaciones:
López-Aladid, R:
 Univ Barcelona, Inst Invest Biomed August Pi I Sunyer FRCB IDIBAPS, Ctr Invest Biomed Red Enfermedades Resp CIBERES 06, Sch Med,Cellex Lab,Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Hosp Clin Barcelona, Pulmonol Serv, Barcelona, Spain

Bueno-Freire, L:
 Univ Barcelona, Inst Invest Biomed August Pi I Sunyer FRCB IDIBAPS, Ctr Invest Biomed Red Enfermedades Resp CIBERES 06, Sch Med,Cellex Lab,Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Hosp Clin Barcelona, Pulmonol Serv, Barcelona, Spain

Farriol-Duran, R:
 Canc Immunogen Inst Josep Carreras, Barcelona, Spain

 Barcelona Supercomp Ctr BSC, Barcelona, Spain

:
 Canc Immunogen Inst Josep Carreras, Barcelona, Spain

 Barcelona Supercomp Ctr BSC, Barcelona, Spain

Aguilar, R:
 ISGlobal, Barcelona, Spain

Vidal, M:
 ISGlobal, Barcelona, Spain

Jiménez, A:
 ISGlobal, Barcelona, Spain

 Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Barcelona, Spain

Cabrera, R:
 Univ Barcelona, Inst Invest Biomed August Pi I Sunyer FRCB IDIBAPS, Ctr Invest Biomed Red Enfermedades Resp CIBERES 06, Sch Med,Cellex Lab,Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Hosp Clin Barcelona, Pulmonol Serv, Barcelona, Spain

Vázquez, N:
 Univ Barcelona, Inst Invest Biomed August Pi I Sunyer FRCB IDIBAPS, Ctr Invest Biomed Red Enfermedades Resp CIBERES 06, Sch Med,Cellex Lab,Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Hosp Clin Barcelona, Pulmonol Serv, Barcelona, Spain

López-Gavín, A:
 Univ Barcelona, Inst Invest Biomed August Pi I Sunyer FRCB IDIBAPS, Ctr Invest Biomed Red Enfermedades Resp CIBERES 06, Sch Med,Cellex Lab,Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Hosp Clin Barcelona, Pulmonol Serv, Barcelona, Spain

Moncunill, G:
 ISGlobal, Barcelona, Spain

 Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Barcelona, Spain

Carrascal, M:
 Spanish Natl Res Council IIBB CSIC IDIBAPS, Inst Biomed Res Barcelona, Biol & Environm Prote Grp, Barcelona, Spain

García, T:
 Spanish Natl Res Council IIBB CSIC IDIBAPS, Inst Biomed Res Barcelona, Biol & Environm Prote Grp, Barcelona, Spain

Lozano, M:
 Univ Barcelona ES, Hosp Clin, Inst Clin Canc & Malalties Sang, Inst Invest Biomed August Pi I Sunyer FRCB IDIBAPS, Barcelona, Spain

García-Basteiro, AL:
 ISGlobal, Barcelona, Spain

 Spanish Consortium Res Epidemiol & Publ Hlth CIBER, Barcelona, Spain

 Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Barcelona, Spain

Dobaño, C:
 ISGlobal, Barcelona, Spain

 Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Barcelona, Spain

Pazos, MD:
 Catalan Inst Nanosci & Nanotechnol ICN2, Nanobiosensors & Bioanalyt Applicat Grp NanoB2A, CSIC, CIBER BBN,BIST, Bellaterra, Barcelona, Spain

Estevez, MC:
 Catalan Inst Nanosci & Nanotechnol ICN2, Nanobiosensors & Bioanalyt Applicat Grp NanoB2A, CSIC, CIBER BBN,BIST, Bellaterra, Barcelona, Spain

Lechuga, LM:
 Catalan Inst Nanosci & Nanotechnol ICN2, Nanobiosensors & Bioanalyt Applicat Grp NanoB2A, CSIC, CIBER BBN,BIST, Bellaterra, Barcelona, Spain

Torres, A:
 Univ Barcelona, Inst Invest Biomed August Pi I Sunyer FRCB IDIBAPS, Ctr Invest Biomed Red Enfermedades Resp CIBERES 06, Sch Med,Cellex Lab,Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Hosp Clin Barcelona, Pulmonol Serv, Barcelona, Spain

Fernández-Barat, L:
 Univ Barcelona, Inst Invest Biomed August Pi I Sunyer FRCB IDIBAPS, Ctr Invest Biomed Red Enfermedades Resp CIBERES 06, Sch Med,Cellex Lab,Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Hosp Clin Barcelona, Pulmonol Serv, Barcelona, Spain
ISSN: 20452322





Scientific Reports
Editorial
Nature Publishing Group, HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY, Reino Unido
Tipo de documento: Article
Volumen: 15 Número: 1
Páginas: 16269-16269
WOS Id: 001485667500014
ID de PubMed: 40346118
imagen Green Submitted, gold

MÉTRICAS